确定需启动大量输血方案患者的优化补钙剂量
该回顾性单中心队列研究纳入2010年1月1日至2021年7月31日在一级创伤中心启动大量输血方案(MTP)的创伤与外科患者308例,其中165例(53.6%)24小时内离子钙(iCa)<0.9 mmol/L。以枸橼酸克数与补钙毫当量比值(Citrate:Ca)分析,中位比值1.97(IQR 1.14–2.91)与24小时死亡率(P=0.79)及30天死亡率(P=0.91)均无显著关联;24小时与30天死亡率均在Citrate:Ca为2时最低。作者认为Citrate:Ca比值2–3足以在MTP启动后24小时内使iCa正常化,但需进一步前瞻性研究确定最佳比值。
要点
- 在启动MTP的创伤与外科患者中,补钙比值Citrate:Ca中位1.97(IQR 1.14–2.91)与24小时死亡率(P=0.79)和30天死亡率(P=0.91)均无显著关联。
- 24小时死亡率与30天死亡率均在Citrate:Ca为2时最低。
- 308例启动MTP患者中165例(53.6%)在24小时内出现iCa<0.9 mmol/L的严重低钙血症。
- 作者认为Citrate:Ca比值2–3足以在MTP启动后24小时内使iCa正常化, regardless of baseline iCa level。
- 作者指出需进一步前瞻性研究确定最佳Citrate:Ca比值。
适用人群与场景
- 2010年1月1日至2021年7月31日在一级创伤中心需要启动大量输血方案(MTP)的创伤与外科患者,最终纳入308例。
- 排除标准包括基线严重低钙血症,定义为离子钙(iCa)<0.9 mmol/L。
诊断标准与关键阈值
- 严重低钙血症定义为离子钙(iCa)<0.9 mmol/L。
- 补钙比值以枸橼酸克数(g)与补钙毫当量(mEq)之比(Citrate:Ca)表示。
研究设计与关键结果
- 研究类型为回顾性、单中心、队列研究,在一级创伤中心进行,共筛查501例,排除193例,最终纳入308例启动MTP的创伤与外科患者。
- 308例中165例(53.6%)在24小时内iCa<0.9 mmol/L,143例(46.4%)iCa≥0.9 mmol/L。
- Citrate:Ca比值中位1.97(IQR 1.14–2.91)与24小时死亡率无显著关联(P=0.79),与30天死亡率无显著关联(P=0.91)。
- 24小时死亡率与30天死亡率均在Citrate:Ca为2时最低。
- 次要终点包括24小时和30天死亡率、MTP中使用的血液成分及钙剂类型。
证据类型、等级与局限
- 证据类型:回顾性、单中心、队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在接受MTP的患者中,Citrate:Ca比值在2至3之间足以在MTP启动后24小时内获得正常化的iCa, regardless of baseline iCa level。
- 作者指出,需要进一步的前瞻性研究来确定最佳的Citrate:Ca比值。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Massive transfusion protocols (MTP) commonly result in severe hypocalcemia due to the calcium-binding affinity of citrate in blood components. The purpose of this study is to determine the optimal grams (g) of citrate to repletion calcium (Ca) milliequivalents (mEq) (Citrate:Ca) ratio to reduce 30-day mortality.
METHODS: This was a retrospective, single-centered, cohort study at a level 1 trauma center evaluating trauma and surgical patients in need of MTP activation from January 1, 2010-July 31, 2021. Patients with severe hypocalcemia at baseline, defined as ionized calcium (iCa) <0.9 mmol/L, were compared to patients without severe hypocalcemia. The primary endpoint was to determine the optimal ratio of grams of citrate to calcium mEq to reduce mortality in patients receiving a MTP. Secondary endpoints included mortality at 24 h and 30 days, blood components used in MTP, and type of calcium used.
RESULTS: Overall, 501 patients were screened for inclusion. Of these patients, 193 were excluded, leaving 308 patients, of which 165 patients (53.6%) had an iCa <0.9 mmol/L within 24 h and 143 patients (46.4%) had iCa ≥0.9 mmol/L within 24 h. The ratio of Citrate:Ca for each patient was not significantly associated with mortality at 24 h (P = 0.79) or 30 days (P = 0.91) at a repletion Citrate:Ca ratio of median 1.97 (IQR 1.14-2.91). The rate of mortality was lowest at a Citrate:Ca of 2 in both <24-h mortality and 30-day mortality.
CONCLUSIONS: There were no differences in 24 h or 30 day mortality based on repletion ratios seen in this study. A Citrate:Ca ratio between 2 and 3 in patients undergoing MTP was sufficient to obtain a normalized iCa within 24 h of MTP activation regardless of baseline iCa level. Further prospective studies will be needed to determine the optimal Citrate:Ca ratio.
参考来源
- Robinson A, Rech MA, DeChristopher PJ, et al. Defining the optimal calcium repletion dosing in patients requiring activation of massive transfusion protocol. Am J Emerg Med. 2023. PMID: 37245404. doi:10.1016/j.ajem.2023.05.017
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。